99% Pharmaceutical Raw Material Lapatinib CAS 231277-92-2 for Breast Cancer

99% Pharmaceutical Raw Material Lapatinib CAS 231277-92-2 for Breast Cancer

Basic information

Description of Lapatinib

Lapatinib (INN), used in the form of lapatinib ditosylate, (USAN) (Tykerb/Tyverb, GSK) is an orally active drug for breast cancer and other solid tumours. It is a dual tyrosine kinase inhibitor which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways. It is used in combination therapy for HER2-positive breast cancer. It is used for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 (ErbB2).

Usage of .Lapatinib

1.Lapatinib is a breast cancer targeted therapy drug . Breast cancer molecular targeted therapy aims at the occurrence and development of cancer-related genes and their expression products of breast cancer for treatment. Molecular targeted drugs by blocking signal transduction of tumor cells or associated cells , control changes in cell gene expression, in order to inhibit or kill tumor cells.

2.Lapatinib is a novel targeted anti-cancer drug. It Can act on Her-1 and Her-2 two targets at he same time, the biological effect of the inhibition of tumor cell proliferation and growth arising from this mode of action is much larger than acting on just one target. The so-called targeted therapy, refers to certain receptors, genes or proteins as a key target, and then targets to kill tumor cells related to drugs.

99% Pharmaceutical Raw Material Lapatinib CAS 231277-92-2 for Breast Cancer Images